Related Experiment Video
Updated: May 28, 2026
06:21
Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
Published on: May 10, 2024
From Genotype to Functional Risk: A Multi-Omic Approach to Predicting Thiopurine and Methotrexate Co-Therapy-Induced
Dénes Molnár1, Elizabeth Reznik2, Pálma Porrogi3
1Centre for Translational Medicine, Semmelweis University, 1085 Budapest, Hungary.
Pharmaceuticals (Basel, Switzerland)
|May 27, 2026
Summary
Standard thiopurine and methotrexate therapy for acute lymphoblastic leukemia (ALL) risks liver injury due to variable drug metabolism. New approaches are needed to predict and prevent this toxicity beyond current genetic testing.
Area of Science:
- Pharmacogenomics
- Hepatotoxicity
- Drug Metabolism
Background:
- Thiopurine and methotrexate (MTX) co-therapy is standard for acute lymphoblastic leukemia (ALL), but carries risks of drug-induced liver injury (DILI) due to narrow therapeutic windows and inter-individual variability.
- Current pharmacogenetic (PGx) testing for TPMT and NUDT15 variants effectively predicts myelosuppression but often misses DILI, indicating a genotype-phenotype gap.
- MTX-induced metabolic strain and systemic inflammation can destabilize thiopurine detoxification pathways, exacerbating DILI risk.
Purpose of the Study:
- To review the molecular determinants of DILI in ALL co-therapy, focusing on secondary metabolic pathways and transporter dynamics.
- To emphasize the role of cytokine-mediated suppression of CYP450 enzymes and hepatic transporters in DILI.
- To highlight the limitations of current PGx testing and advocate for integrated, real-time risk assessment strategies.
Main Methods:
- Review of current literature on thiopurine and MTX metabolism, focusing on genetic and non-genetic factors influencing toxicity.
- Analysis of molecular mechanisms including cytokine-mediated transcriptional suppression of drug-metabolizing enzymes and transporters.
- Evaluation of nuclear receptor signaling pathways (PXR, CAR, HNF4α) in modulating drug exposure and toxicity.
Main Results:
- Cytokine-mediated suppression of CYP450 enzymes and hepatic transporters (SLCO1B1, ABCC2/4) are primary drivers of DILI, not just secondary modulators.
- Disrupted nuclear receptor signaling leads to functional phenoconversion and toxic molecular shunting, increasing intrahepatic drug exposure.
- Existing PGx testing is insufficient for predicting DILI, underscoring a significant genotype-phenotype discrepancy.
Conclusions:
- Precision therapy for ALL requires moving beyond static PGx testing to comprehensive, real-time risk assessment.
- Integrating gene-environment interactions, multi-omics data, and clinical monitoring is crucial for improving DILI prediction and prevention.
- A transformative strategy combining extended PGx profiling, transcriptomic monitoring, and clinical biomarkers can enhance precision drug delivery and patient outcomes.
Related Concept Videos
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:24Drug Toxicity: Risk factors
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...